Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

28.95 -0.83 (-2.79%)
Streaming Delayed Price Updated: 11:08 AM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
32 33 Next >
News headline image
Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
News headline image
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗
 
Via Benzinga
News headline image
Breaking Down Teva Pharmaceutical Indus: 5 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today ↗
 
Via Benzinga
News headline image
Why Hims & Hers Heath Shares Are Surging Today ↗
Hims & Hers Health Inc. (NYSE: HIMS) shares are moving higher on Monday amidst the announcement of Kåre Schultz's appointment to the Board of Directors. 
Via Benzinga
News headline image
Teva's Migraine Treatment Found Effective For Children As Young As 6 ↗
Teva Pharmaceutical's Phase 3 SPACE study reveals Ajovy's significant efficacy in preventing episodic migraines in children aged 6-17. The trial's primary endpoint was met with safety data aligning... 
Via Benzinga
News headline image
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There' ↗
Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde. 
Via Benzinga
News headline image
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know ↗
 
Via Benzinga
News headline image
3 No-Brainer Stocks to Buy With $200 Right Now ↗
A modest amount of money can go a long way on Wall Street when it's put to work in innovation-driven businesses. 
Via The Motley Fool
News headline image
Here's How Much $1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
FTC Crackdown on Teva Pharmaceuticals Over Inhaler Patent Abuse ↗
The FTC is investigating Teva Pharmaceuticals for alleged misuse of inhaler patents to block generic competition and maintain high prices in the U.S. while selling the same products for less overseas. 
Via Benzinga
Topics Intellectual Property
News headline image
Dr. Reddy's Labs Stock Sees Improved Technical Strength ↗
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76. 
Via Investor's Business Daily
News headline image
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Engages In Settlement Talks Over Medicare Kickback Allegations ↗
Teva Pharmaceutical is negotiating with the DOJ to settle a lawsuit alleging it paid kickbacks through charities to boost Copaxone sales, risking up to $10 billion in damages. 
Via Benzinga
Topics Lawsuit
News headline image
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know ↗
Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly... 
Via Benzinga
Topics Lawsuit
News headline image
7 A-Rated Biotech Stocks Worth Betting on in June ↗
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
News headline image
What is a Bull Flag Pattern? Explanation and Examples
Learn how to identify and trade the bull flag pattern, which is a key tool for spotting continuations in bullish trends. 
Via MarketBeat
News headline image
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
2 Generic Drug Makers With Growing Runways
Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. 
Via MarketBeat
Topics Intellectual Property
News headline image
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.